PPARG and Hyperglycemia: These data indicated that CGA represents a novel PPARγ2 agonist different from RG; however, further study of the regulation mechanism associated with CGA-mediated activity on lipid metabolism is necessary to provide insight to its potential application for preventing insulin resistance and hyperglycemia.